These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23398335)

  • 1. The rational use of animals in drug development: contribution of the innovative medicines initiative.
    Magda G; Vaudano E; Goldman M
    Altern Lab Anim; 2012 Dec; 40(6):307-12. PubMed ID: 23398335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Innovative Medicines Initiative moves translational immunology forward.
    Goldman M; Wittelsberger A; De Magistris MT
    Eur J Immunol; 2013 Feb; 43(2):298-302. PubMed ID: 23534061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 6. Public-private partnerships as driving forces in the quest for innovative medicines.
    Goldman M; Compton C; Mittleman BB
    Clin Transl Med; 2013 Jan; 2(1):2. PubMed ID: 23369569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The innovative medicines initiative: a public private partnership model to foster drug discovery.
    Vaudano E
    Comput Struct Biotechnol J; 2013; 6():e201303017. PubMed ID: 24688725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflections on the Innovative Medicines Initiative.
    Goldman M
    Nat Rev Drug Discov; 2011 May; 10(5):321-2. PubMed ID: 21532547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Innovative Medicine Initiative (IMI)].
    Bril A; Canet E
    Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.
    Laverty H; Meulien P
    Front Med (Lausanne); 2019; 6():275. PubMed ID: 31850354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Innovative Medicines Initiative: Progress to Date.
    Faure JE; Dyląg T; Norstedt I; Matthiessen L
    Pharmaceut Med; 2018; 32(4):243-249. PubMed ID: 30174434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Partnership for Alternative Approaches to Animal Testing (EPAA): promoting alternative methods in Europe and beyond.
    Cozigou G; Crozier J; Hendriksen C; Manou I; Ramirez-Hernandez T; Weissenhorn R
    J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):209-13. PubMed ID: 25836968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks.
    O'Rourke D; Coll-Padrós N; Bradshaw A; Killin L; Pradier L; Georges J; Dawoud DM; Steukers L; Diaz C
    Front Neurol; 2022; 13():994301. PubMed ID: 36408524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enabling personalized medicine in Europe by the European Commission's funding activities.
    Nimmesgern E; Norstedt I; Draghia-Akli R
    Per Med; 2017 Jul; 14(4):355-365. PubMed ID: 29749834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Innovative Medicines Initiative: an engine for regulatory science.
    Goldman M; Seigneuret N; Eichler HG
    Nat Rev Drug Discov; 2015 Jan; 14(1):1-2. PubMed ID: 25503331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of medicines and the use of animals in research.
    Balkwill F; Whitehead S; Willis P; Gaymond N; Kent A; Page C; Lovell-Badge R; Morris R; Lemon R; Banks D
    Lancet; 2011 Jul; 378(9786):127-8. PubMed ID: 21719093
    [No Abstract]   [Full Text] [Related]  

  • 20. Working in partnership to advance the 3Rs in toxicity testing.
    Holmes AM; Creton S; Chapman K
    Toxicology; 2010 Jan; 267(1-3):14-9. PubMed ID: 19903508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.